Q4 2025 Nykode Therapeutics ASA Earnings Call Transcript
Key Points
- Nykode Therapeutics AS (VACBF) is well-capitalized with a cash runway extending into 2028, providing financial stability for ongoing projects.
- The company has made significant progress with its lead asset, Abi-Suva, showing an objective response rate of 38.5% in first-line head and neck cancer, which is significantly higher than the current standard of care.
- Nykode's NeoSELECT algorithm, a machine learning-driven tool, has been granted a US patent, enhancing its individualized neoantigen therapy capabilities.
- The company has received fast approval from UK authorities for its clinical trial applications, indicating efficient regulatory progress.
- Nykode is actively engaging with potential partners and key opinion leaders to advance its antigen-specific immune tolerance platform, which shows promise in addressing autoimmune diseases and allergies.
- Nykode reported no revenue for the fourth quarter of 2025, compared to $6.8 million in the same period of 2024, due to the cancellation of an agreement with Genentech.
- The company recorded a net loss of $8 million for the fourth quarter, an increase from the $6.8 million loss in the same period of 2024.
- Operating expenses are expected to increase as the company progresses with its clinical trials, potentially impacting financials.
- There is uncertainty regarding the outcome of a pending tax case, which could affect the company's cash runway if not resolved favorably.
- Nykode is not guiding on any revenue from partnerships in 2026, indicating potential challenges in securing immediate financial collaborations.
Greetings and welcome to the Nykode Therapeutics Q4 2025 financial results presentation. At this time, all participants are in listen-only mode.
(Operator Instructions) As a reminder, this conference is being recorded. It's not my pleasure to introduce Chief Executive Officer Michael Engsig. Please go ahead, sir.
Thank you very much, Kevin, and I very warm welcome to all participants at this quarterly presentation from NCO where we look forward to take you through the fourth quarter and achievements happening subsequent to the quarter. Just a quick reminder before we start off the forgoing statement, we assume you are all familiar with these statements and that we will move forward.
Happy to again have with me here today in the room, Aita Fredriksson, our co-founder and Chief Scientific Officer and Health Business Development. Who will take us through, a deeper dive on our status for the new program and our tolerance program, as well as H Guggen, our CFO, who will take you
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
